期刊
TRANSLATIONAL ONCOLOGY
卷 13, 期 1, 页码 17-24出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.tranon.2019.09.003
关键词
-
类别
资金
- Central Norway Regional Health Authority [2014/23203]
- Norwegian University of Science and Technology (NTNU) [2014/23203]
- St. Olavs University Hospital research funding 2014
- St. Olavs University Hospital research funding 2016
- Research Council of Norway through its Centres of Excellence Scheme [223255/F50]
Lung cancer is the leading cause of cancer death in both sexes worldwide and has a predicted 5-year survival rate of <20%. Immunotherapy targeting immune checkpoints such as the programmed death 1 (PD-1) signaling pathway has led to a shift of paradigm in the treatment of advanced non-small-cell lung cancer (NSCLC) but remains without effect in similar to 80% of patients. Accumulating evidence suggests that several immunosuppressive mechanisms may work together in NSCLC. The contribution and cooperation between different immunosuppressive mechanisms in NSCLC remain unknown. Recently, the CD39-adenosine pathway has gained increasing attention as a crucial immunosuppressive mechanism and possible target for immunotherapy. Immune cells were extracted from lung and tumor tissue after lung resection in 12 patients by combined enzymatic and mechanical tissue disaggregation. A multiparameter flow cytometry panel was established to investigate the expression and coexpression of CD39 and PD-1 on key lymphocyte subtypes. Frequencies of CD39(+), PD-1(+), and CD39(+)/PD-1(+) cells were higher among both CD4(+) and CD8(+)T cells isolated from NSCLC tumor tissue than in T cells from normal lung tissue. Similarly, the frequency of FoxP3(+) CD4(+)T cells (Tregs) was highly significantly elevated in tumor tissue compared to adjacent lung tissue. The consistent upregulation of CD39 on immune cells in tumor microenvironment indicates that the CD39 signaling pathway may, in addition to the PD-1 pathway, represent another important mechanism for tumor-induced immunosuppression in NSCLC. In addition, the present study indicates that a comprehensive immune response profiling with flow cytometry may be both feasible and clinically relevant.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据